RCMNY
RETA

Rubric Capital Management (New York)’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Rubric Capital Management (New York)’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-138,556
Closed -$4.54M – 98
2022
Q1 		$4.54M Buy
+138,556
New +$4.11M 0.16% 59

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rubric Capital Management (New York)'s RETA Position: Q2 2022 in Review

Rubric Capital Management (New York) sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2022, closing a stake of 138,556 shares — an estimated $4.54M sold.

Rubric Capital Management (New York) first reported a position in RETA in Q1 2022 and held it in 1 quarter. The position peaked at $4.54M in Q1 2022. 146 funds tracked by Wall St. Rank hold RETA as of Q2 2022.

  • Rubric Capital Management (New York) reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2022 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 138,556 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2022, an estimated $4.54M.
  • Rubric Capital Management (New York) first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2022 and held it in 1 quarter.
  • Rubric Capital Management (New York)'s Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $4.54M in Q1 2022.
  • 146 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2022.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2022, filed 12 Aug 2022.